- Home
- EPSM vs CELU Comparison
EPSM vs CELU Comparison
Compare EPSM & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSM | CELU |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 17.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EPSM | CELU |
|---|---|---|
| Price | $1.57 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 726.7K | ★ 10.9M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,550,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $0.56 |
| 52 Week High | $42.45 | $2.55 |
Technical Indicators
Market Signals| Indicator | EPSM | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 46.64 |
| Support Level | $1.33 | $1.10 |
| Resistance Level | $1.59 | $1.43 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 50.14 | 2.50 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohols.
About CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.